ReviewIndian journal of ophthalmology2020
Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.
Review in Indian journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 86 citations in OpenAlex.
- Identification of natural peptides from "PlantPepDB" database as anti-SARS-CoV-2 agents: A protein-protein docking approach.Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2023Article
- Antiviral Potential of Plants against COVID-19 during Outbreaks-An Update.International journal of molecular sciences · 2022Review
- In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease.Molecules (Basel, Switzerland) · 2022Review
- Overview of Hydroxychloroquine and Remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Journal of heterocyclic chemistry · 2022Review
- SARS-CoV-2 variants and vulnerability at the global level.Journal of medical virology · 2022Review
- Effects of Plant Metabolites on the Growth of COVID-19 (Coronavirus Disease-19) Including Omicron Strain.Cureus · 2022Review
- The impact of COVID-19 related national lockdown on ophthalmic emergency in Italy: A multicenter study.European journal of ophthalmology · 2022Article
- Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2022Article
- Synthesis, spectroscopic, and computational studies on molecular charge-transfer complex of 2-((2-hydroxybenzylidene) amino)-2-(hydroxymethyl) propane-1, 3-diol with chloranilic acid: Potential antiviral activity simulation of CT-complex against SARS-CoV-2.Journal of molecular structure · 2022Article
- Network analytics for drug repurposing in COVID-19.Briefings in bioinformatics · 2022Article
- Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.Frontiers in immunology · 2022Review
- Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients.Journal of drug delivery science and technology · 2022Review
- Article
- Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn.Gene reports · 2021Review
- Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view.Biochimica et biophysica acta. General subjects · 2021Review
- Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.Journal of medical virology · 2021Review
- Intricate scientometric analysis and citation trend of COVID-19-related publications in Indian Journal of Ophthalmology during COVID-19 pandemic.Indian journal of ophthalmology · 2021Article
- Plants and Natural Products with Activity against Various Types of Coronaviruses: A Review with Focus on SARS-CoV-2.Molecules (Basel, Switzerland) · 2021Review
- The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19.International immunopharmacology · 2021Review
- Stem cell therapy in coronavirus disease 2019: current evidence and future potential.Cytotherapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.